To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Cat. No.: TDLD-0825-LD16
Gluc mRNA-LNP
Gluc mRNA-LNP is a state-of-the-art messenger RNA (mRNA) lipid nanoparticle (LNP) system, specifically engineered for efficient in vitro and in vivo protein expression. This LNP encapsulates mRNA encoding Gaussia Luciferase (Gluc), serving as an excellent tool for sensitive bioluminescent reporter assays, enabling real-time monitoring of gene expression, and facilitating studies of cellular trafficking and secretion dynamics. Engineered with a proprietary lipid formulation for optimal mRNA encapsulation and delivery, it ensures high translation efficiency. We offer flexibility in lipid composition, including DLin-MC3-DMA, LP-01, ALC-0315, SM102, and targeted lipids for specific tissues (lung, liver, spleen, muscle), allowing for tailored delivery strategies. Our LNP ensures uniform particle size, high encapsulation efficiency, stability, and effective delivery. Applications of Gluc mRNA-LNP include high-throughput screening (HTS), assessing LNP formulation performance, studying cellular uptake, expression kinetics, and secretion pathways, and serving as a sensitive, secreted reporter system in various biological research contexts. Please note that this product is intended for research purposes only.
Inquiry
SPECIFIC INQUIRY
Clear AllInquiry
For Research Use Only. Not for Diagnostic or Treatment Applications.
Payload Type
mRNA
Payload
Gaussia Luciferase mRNA
Capping
Cap 1
Modification
Unmodified; N1-methyl-pseudouridine; 5-methoxyuridine; Other
Creatibe Biolabs' custom LNP was the only solution that
successfully delivered our CRISPR-Cas9 payload across the blood-brain barrier with high
efficiency and low toxicity.”
Dr. Evelyn Reed
Postdoctoral Researcher, Leading
University
Our siRNA candidate was failing due to off-target toxicity, but
Creatibe Biolabs' team rapidly redesigned our LNP using their modular platform, rescuing our
preclinical program.”
Ben Carter
Project Manager
Achieving cytosolic delivery of our protein degrader with Creatibe Biolabs' exosome platform
was the key to unlocking our candidate's full therapeutic potential.”
Dr. Kenji Tanaka
Principal Scientist, Large
Pharma Corp
Our oncology drug's efficacy was limited by poor tumor
accumulation. Creatibe Biolabs' peptide-conjugated liposomes provided the precise targeting
we needed, dramatically increasing the drug's therapeutic index.”
Dr. Clara Schmidt
Senior Scientist, Oncology
Innovations Inc.
We required a delivery system that would only release its payload
in the tumor's acidic microenvironment. Creatibe Biolabs' pH-responsive liposomes performed
flawlessly, minimizing systemic exposure.”
David Chen
Formulation Scientist
Outstanding expertise in antibody engineering.The team's attention
to detail and innovative approaches have sianificantly accelerated our development timeline.
